AU2001288025A1 - Peptide conjugated anti-cancer prodrugs - Google Patents

Peptide conjugated anti-cancer prodrugs

Info

Publication number
AU2001288025A1
AU2001288025A1 AU2001288025A AU8802501A AU2001288025A1 AU 2001288025 A1 AU2001288025 A1 AU 2001288025A1 AU 2001288025 A AU2001288025 A AU 2001288025A AU 8802501 A AU8802501 A AU 8802501A AU 2001288025 A1 AU2001288025 A1 AU 2001288025A1
Authority
AU
Australia
Prior art keywords
conjugated anti
peptide conjugated
cancer
cancer prodrugs
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288025A
Other languages
English (en)
Other versions
AU2001288025A8 (en
Inventor
Stela Gengrinovitch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosight Ltd
Original Assignee
Biosight Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosight Ltd filed Critical Biosight Ltd
Publication of AU2001288025A1 publication Critical patent/AU2001288025A1/en
Publication of AU2001288025A8 publication Critical patent/AU2001288025A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001288025A 2000-09-05 2001-09-05 Peptide conjugated anti-cancer prodrugs Abandoned AU2001288025A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22973300P 2000-09-05 2000-09-05
US60/229,733 2000-09-05
PCT/IL2001/000839 WO2002020715A2 (en) 2000-09-05 2001-09-05 Peptide conjugated anti-cancer prodrugs

Publications (2)

Publication Number Publication Date
AU2001288025A1 true AU2001288025A1 (en) 2002-03-22
AU2001288025A8 AU2001288025A8 (en) 2006-11-02

Family

ID=22862481

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288025A Abandoned AU2001288025A1 (en) 2000-09-05 2001-09-05 Peptide conjugated anti-cancer prodrugs

Country Status (7)

Country Link
US (2) US7135547B2 (https=)
EP (2) EP2272947B1 (https=)
AT (1) ATE466069T1 (https=)
AU (1) AU2001288025A1 (https=)
DE (1) DE60141992D1 (https=)
IL (1) IL154696A (https=)
WO (1) WO2002020715A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
NZ564694A (en) * 2003-04-22 2009-11-27 Sod Conseils Rech Applic Peptide vectors
AU2004248138B2 (en) * 2003-05-29 2009-09-03 The Scripps Research Institute Targeted delivery to legumain-expressing cells
AT412785B (de) 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
US7345069B2 (en) * 2004-04-02 2008-03-18 Wisconsin Alumni Research Foundation Oxidative activation and episulfonium ion-mediated DNA alkylation-based anticancer
CA2623236A1 (en) * 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
CN101374856A (zh) * 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成
KR20090088946A (ko) * 2006-12-14 2009-08-20 메다렉스, 인코포레이티드 씨디70에 결합하는 인간 항체 및 이의 용도
WO2008139457A2 (en) * 2007-05-10 2008-11-20 Clear Direction Ltd. Methods and compositions for drug targeting
KR101032860B1 (ko) * 2008-10-22 2011-05-06 한국식품연구원 췌장 조직 특이적 유전자 ｍｍｐ1
CN101747411B (zh) * 2008-11-28 2012-07-25 北京大学 氨基酰色氨酰色氨酸三肽苄酯及其制备方法和应用
EP2488874A4 (en) * 2009-10-13 2013-08-14 Univ Johns Hopkins BIOMARKERS FOR THE IDENTIFICATION OF MELANOMOTUM CELLS
AR077384A1 (es) 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
HRP20150664T1 (hr) * 2010-12-03 2015-07-31 Adamed Sp. Z O.O. Antikancerogeni fuzijski protein
PL394618A1 (pl) * 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
US9081001B2 (en) 2012-05-15 2015-07-14 Wellstat Diagnostics, Llc Diagnostic systems and instruments
US9213043B2 (en) 2012-05-15 2015-12-15 Wellstat Diagnostics, Llc Clinical diagnostic system including instrument and cartridge
US9625465B2 (en) 2012-05-15 2017-04-18 Defined Diagnostics, Llc Clinical diagnostic systems
US8946163B2 (en) * 2012-11-19 2015-02-03 Mimedx Group, Inc. Cross-linked collagen comprising metallic anticancer agents
US9155799B2 (en) 2012-11-19 2015-10-13 Mimedx Group, Inc. Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent
US8940684B2 (en) 2012-11-19 2015-01-27 Mimedx Group, Inc. Cross-linked collagen comprising an antifungal agent
US10029030B2 (en) 2013-03-15 2018-07-24 Mimedx Group, Inc. Molded placental tissue compositions and methods of making and using the same
US10335433B2 (en) 2013-04-10 2019-07-02 Mimedx Group, Inc. NDGA polymers and metal complexes thereof
US9446142B2 (en) 2013-05-28 2016-09-20 Mimedx Group, Inc. Polymer chelator conjugates
US10449220B2 (en) 2013-08-30 2019-10-22 Mimedx Group, Inc. Micronized placental compositions comprising a chelator
KR102272213B1 (ko) * 2014-07-08 2021-07-01 삼성전자주식회사 표적화 부위, 절단 부위, 및 세포막 투과 부위를 포함하는 융합 단백질 및 그의 용도
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
US11104698B2 (en) 2015-12-03 2021-08-31 Biosight Ltd. Salts of conjugates for cancer therapy
US11939609B2 (en) 2017-07-24 2024-03-26 The Board Of Trustees Of The Leland Stanford Junior University Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system
CA3086751A1 (en) * 2018-01-08 2019-07-11 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides
KR102544277B1 (ko) * 2020-01-15 2023-06-16 재단법인대구경북과학기술원 세포외 기질 및 항암제로 이루어진 접합체 및 이의 의학적 용도
US20210402001A1 (en) * 2020-06-30 2021-12-30 David I. Cohen Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers
TW202328170A (zh) * 2021-09-14 2023-07-16 美商艾希利歐發展股份有限公司 可裂解連接子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983000150A1 (en) * 1981-07-02 1983-01-20 Walton, Alan, G. Glycosaminoglycan drug complexes
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
CA2157388C (en) * 1993-03-01 1998-12-15 Daniel P. Witt Analogs for specific oligosaccharide-protein interactions and uses thereof
AU684498B2 (en) 1993-03-25 1997-12-18 Merck & Co., Inc. Inhibitor of vascular endothelial cell growth factor
US5612474A (en) * 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
US5871723A (en) 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
CN101374856A (zh) * 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成

Also Published As

Publication number Publication date
EP1581615B1 (en) 2010-04-28
US20030216298A1 (en) 2003-11-20
IL154696A0 (en) 2003-09-17
EP1581615A2 (en) 2005-10-05
DE60141992D1 (https=) 2010-06-10
US7135547B2 (en) 2006-11-14
ATE466069T1 (de) 2010-05-15
US20070160573A1 (en) 2007-07-12
EP1581615A4 (en) 2005-10-05
WO2002020715A2 (en) 2002-03-14
EP2272947A1 (en) 2011-01-12
EP2272947B1 (en) 2016-08-10
AU2001288025A8 (en) 2006-11-02
WO2002020715A3 (en) 2006-01-12
US7638127B2 (en) 2009-12-29
IL154696A (en) 2008-11-03

Similar Documents

Publication Publication Date Title
AU2001288025A1 (en) Peptide conjugated anti-cancer prodrugs
WO2002000263A3 (en) Tripeptide prodrug compounds
WO2001062300A3 (en) Caspase activated prodrugs therapy
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
WO2000061788A3 (en) Poly(dipeptide) as a drug carrier
WO2002013873A3 (en) P97-active agent conjugates and their methods of use
DE60006100D1 (de) Lang wirkende insulinotrope peptide
EP2261200A3 (en) Modified forms of pharmacacologically active agents and uses therefor
KR970700771A (ko) 비-바이러스 벡터(Non-viral vector)
GR3035593T3 (en) Combination of necrosis inducing substances with substances which are activated by necrosis for the selective treatment of tumours and or inflammatory diseases
DE69931925D1 (de) 2-chinolonen enthaltende arzneimittel
RU2010127336A (ru) Фармацевтический препарат для лечения доброкачественной гиперплазии предстательной железы
AU2001264515A1 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
HU9403343D0 (en) New pharmaceutical uses of krill enzymes
WO2002053090A3 (fr) Association medicamenteuse d'une biguanine (metformine) et d'arginine
HRP20030002A2 (en) STABLE GABAPENTIN HAVING pH WITHIN A CONTROLLED RANGE
WO2002098465A3 (en) Cell penetrating therapeutic agents
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
AU3739500A (en) Protease resistant flint analogs
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
AU2002326070A1 (en) Peyers's patch and/or m-celle targeting ligands
WO2005002516A3 (en) Leukocyte internalized peptide-drug conjugates
HK1043534A1 (zh) 蛋白酶抑制剂
WO2001022917A8 (en) Effervescent compositions comprising nimesulide
ATE301469T1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase